A detailed history of Harding Loevner LP transactions in Abb Vie Inc. stock. As of the latest transaction made, Harding Loevner LP holds 830,980 shares of ABBV stock, worth $146 Million. This represents 0.96% of its overall portfolio holdings.

Number of Shares
830,980
Previous 852,023 2.47%
Holding current value
$146 Million
Previous $146 Million 12.29%
% of portfolio
0.96%
Previous 0.83%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$163.84 - $199.33 $3.45 Million - $4.19 Million
-21,043 Reduced 2.47%
830,980 $164 Million
Q2 2024

Aug 14, 2024

SELL
$154.79 - $180.76 $4.06 Million - $4.74 Million
-26,217 Reduced 2.99%
852,023 $146 Million
Q1 2024

May 15, 2024

SELL
$159.82 - $182.1 $12.2 Million - $13.9 Million
-76,397 Reduced 8.0%
878,240 $160 Million
Q4 2023

Feb 14, 2024

SELL
$137.6 - $154.97 $1.89 Million - $2.13 Million
-13,719 Reduced 1.42%
954,637 $148 Million
Q3 2023

Nov 14, 2023

BUY
$133.59 - $154.65 $16.1 Million - $18.6 Million
120,463 Added 14.21%
968,356 $144 Million
Q2 2023

Aug 14, 2023

SELL
$132.51 - $164.9 $21.1 Million - $26.3 Million
-159,424 Reduced 15.83%
847,893 $114 Million
Q1 2023

May 15, 2023

BUY
$144.61 - $166.54 $146 Million - $168 Million
1,007,317 New
1,007,317 $161 Million
Q1 2022

May 16, 2022

SELL
$131.98 - $163.75 $27,715 - $34,387
-210 Reduced 24.79%
637 $96,000
Q1 2021

May 17, 2021

BUY
$102.3 - $112.62 $52,684 - $57,999
515 Added 155.12%
847 $92,000
Q3 2020

Nov 16, 2020

BUY
$85.91 - $100.83 $15,463 - $18,149
180 Added 118.42%
332 $29,000
Q1 2020

May 15, 2020

BUY
$64.5 - $97.79 $9,804 - $14,864
152 New
152 $12,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Harding Loevner LP Portfolio

Follow Harding Loevner LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Harding Loevner LP, based on Form 13F filings with the SEC.

News

Stay updated on Harding Loevner LP with notifications on news.